NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
NRx Defense Systems, a subsidiary of NRx Pharmaceuticals (NRXP), received an $11.18M DARPA contract to evaluate robotic magnetic stimulation with NRX-101 for treating resistant depression. The SPARC-TMS trial, led by Harvard, ASU, and others, aims to replicate 91% response rates from prior studies. Success could support FDA approval for NRX-101 in this indication.
How this was made
The 30-second read
Why it matters
If successful, the trial could become the basis for FDA registration of NRX‑101 with TMS, opening a sizable market.
Market read
The award provides a new catalyst for NRXP and may attract attention to defense‑focused biotech initiatives.
What to watch
Potential regulatory delays and the need for successful trial data before any market move.
Background
DARPA seeks deployable mental‑health treatments for military personnel; NRx Defense is positioned to deliver a one‑day TMS solution.
Ticker impact
NRx Pharmaceuticals (Nasdaq:NRXP) subsidiary NRx Defense Systems received an $11.1M DARPA contract for the SPARC‑TMS trial.
likely modest upside as investors price in the contract and potential FDA pathway.
The contract is a new, material catalyst for the parent biotech, but the dollar amount is modest and the trial outcome is still uncertain.
Market effects
Highlights growing defense‑biotech crossover; may spur interest in other neuro‑plasticity programs.
U.S. market, especially biotech and defense sectors.
Limited to firms with similar defense‑medical collaborations.
Counterpoint
The contract size is small and trial risk high; investors may remain cautious.
Key entities
- companyNRx Defense Systems
Subsidiary of NRx Pharmaceuticals developing the SPARC‑TMS protocol.
- government_agencyDARPA
U.S. Defense Advanced Research Projects Agency funding the contract.
